Chromogranin A staining as a biomarker for prostate adenocarcinoma
As reported in The Prostate, chromogranin A (CgA) staining, an indicator of neuroendocrine differentiation, is associated with decreased biochemical control, clinical failure, increased distant metastases, and decreased cause-specific survival in patients with prostate adenocarcinoma and a GS ≥ 7 (n=285). The median follow-up was 6.5 y. CgA staining was present in 31% of specimens. The 10-y distant metastases rate in specimens with <1% and >1% CgA staining was 8% and 48%, respectively. The 10-y cause-specific survival in specimens with <1% and >1% CgA staining was 95% vs. 76%, respectively.
High expression of MUC1 + HER3 is associated with favorable outcome in bladder cancer patients
As reported in BJU International, elevated co-expression of MUC1 + HER3 was associated with improved survival in patients with bladder cancer. MUC1 alone, or elevated MUC1 + non-elevated HER3, had no prognostic value. Moreover, MUC1 was not predictive of survival, tumor stage, or tumor grade.
PCA3 useful for early diagnosis of prostate cancer
Based on a meta-analysis reported in the Chinese Medical Journal, prostate cancer antigen 3 (PCA3) can be used for the early diagnosis of prostate cancer and to avoid unnecessary biopsies, with a sensitivity of 0.82, a specificity of 0.962, a positive likelihood ratio of 2.39, a negative likelihood ratio of 0.51, and a diagnostic odds ratio of 4.89.